Table 2.
I. Economic and clinical outcomes | ||||||
---|---|---|---|---|---|---|
HIV-infected infants | HIV-exposed infants | |||||
EID strategy | One-year survival (%) | Life expectancy (years, undiscounted) | Lifetime costs (2016 USD, per person) | One-year survival (%) | Life expectancy (years, undiscounted) | Lifetime costs (2016 USD, per person) |
Conventional | 69·0 | 22·7 | $11,830 | 93· 1 | 62·5 | $610 |
POC | 78·0 | 25·5 | $13,460 | 93·4 | 62·6 | $690 |
II. Incremental cost-effectiveness ratios (ICERs) | ||||||
EID strategy | HIV-exposed life expectancy (years, discounted) | HIV-exposed lifetime costs (USD per person, discounted) | Incremental cost-effectiveness ratio ($/YLS) | |||
Conventional | 25·69 | $370 | Comparator | |||
POC | 25·77 | $420 | $680 |
Abbreviations: POC: point-of-care; EID: early infant HIV diagnosis; HIV: human immunodeficiency virus; USD: United States dollar; ICER: incremental cost-effectiveness ratio; YLS: year of life saved.